StockData
Aquestive Therapeutics, Inc. logo

Aquestive Therapeutics, Inc. (AQST) company profile

AQSTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 3/30
$3.70−0.06 (-1.60%)

Close on Nov 17, 2026Market cap $464.39MP/E –Yield –

About Aquestive Therapeutics

Pharmaceutical Preparations, SIC 2834

Aquestive Therapeutics is a pharmaceutical company that develops and manufactures medicines using proprietary drug delivery technologies, such as its PharmFilm oral soluble film and AdrenaVerse epinephrine prodrug platform. The company designs alternatives to invasive administrations for conditions including severe allergic reactions, central nervous system disorders, and opioid dependence. Its pipeline includes Anaphylm sublingual film for anaphylaxis and AQST-108 topical gel for alopecia areata. Aquestive also collaborates with pharmaceutical partners, serving as an exclusive manufacturer for commercialized licensed products such as Suboxone, Sympazan, and Ondif. Its customers and end users include commercial licensee partners, healthcare providers, and patients requiring alternative drug administration methods.

The company operates manufacturing facilities located in Portage, Indiana, and maintains corporate headquarters along with primary research laboratories in Warren, New Jersey. Aquestive has produced and shipped more than two billion doses of oral films globally, with commercial products distributed in the United States and international markets.

Summary of the business section of Aquestive Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Aquestive Therapeutics, Inc.
Headquarters
Warren, NJ
Address
184 Liberty Corner Road, Suite 305
Phone
(908) 941-1900
Employees
147, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
KPMG LLP, Short Hills, New Jersey

Stock & identifiers

Ticker
AQST
Exchange
Nasdaq
IPO date
Jul 25, 2018
Shares outstanding
126M, Aug 7, 2026
Public float
$291.60M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
SEC CIK
1398733
CUSIP
03843E104
ISIN
US03843E1047
FIGI
BBG00L9HP0Z0
Share class FIGI
BBG00L9HP1R7
EIN
20-8623253

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Daniel BarberPresident and CEO, Director627,317
Matthew W. DavisChief Development Officer87,500
Sherry KorczynskiChief Commercial Officer235,689
Peter E. BoydChief People Officer284,024
Cassie JungChief Operating Officer208,833
Thomas A. ZalewskiChief Legal Officer100,000
Melina CioffiSVP, Regulatory Affairs273,200
Lori J. BraenderCorporate Secretary231,042
A. Ernest Toth JrChief Financial Officer283,460
Matthew J. GreenhawtChief Medical Officer77,000
Carl N. KrausChief Medical Officer282,475
Stephen WargackiChief Science Officer343,552
Richard J. DalyDirector28,025
John CochranDirector161,715
Julie KropDirector0
Timothy E. MorrisDirector–
Abigail L. JenkinsDirector0
Marco TagliettiDirector–
Gregory B. BrownDirector75,085

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$3.49M$11.03M$1.34M$716–
FY2024
Daniel Barber
$4.18M$5.23M$2.55M$395–
FY2024
Keith Kendall
$0$0$2.55M$395–
FY2023
Daniel Barber
$2.50M$3.28M$1.15M$224–
FY2023
Keith Kendall
$0$0$1.15M$224–
FY2022$1.33M$704.73K$872.97K$23–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payTotalvs. prior year
Daniel Barber
President and Chief Executive Officer
$659.89K$1.55M$877.20K$409.13K$3.49M-16%
Lori J. Braender
Corporate Secretary, Former Chief Legal Officer and Chief Compliance Officer*
$457.96K$524.15K$129.00K$237.13K$1.35M-26%
A. Ernest Toth, Jr.
Chief Financial Officer**
$442.60K$524.15K$129.00K$227.80K$1.32M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we employed approximately 147 colleagues.”

Corporate history

Events identified from SEC filings

DateEventDetails
Jan 3, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jul 15, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jul 20, 2018ListingRegistration of securities on an exchange (Form 8-A)
Mar 27, 2008Name changeName changed from MonoSol Rx, Inc. to Aquestive Therapeutics, Inc.

See a number that looks wrong?